Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
O43237
UPID:
DC1L2_HUMAN
Alternative names:
Dynein light intermediate chain 2, cytosolic; LIC53/55
Alternative UPACC:
O43237; A8K6V1; B4DZP4; Q8TAT3
Background:
Cytoplasmic dynein 1 light intermediate chain 2, also known as Dynein light intermediate chain 2, cytosolic or LIC53/55, plays a crucial role in the cytoplasmic dynein 1 complex. This protein is instrumental in linking dynein to cargos and adapter proteins, facilitating the retrograde motility of vesicles and organelles along microtubules. Its involvement in binding dynein to membranous organelles or chromosomes underscores its significance in cellular transport mechanisms.
Therapeutic significance:
Understanding the role of Cytoplasmic dynein 1 light intermediate chain 2 could open doors to potential therapeutic strategies. Its pivotal function in intracellular transport makes it a compelling target for drug discovery, aiming to modulate cellular processes implicated in various diseases.